Roche/Genentech gain FDA nod for Tamiflu in babies as young as 2 weeks
This article was originally published in Scrip
Executive Summary
The US FDA has given its seal of approval for Roche subsidiary Genentech to market its influenza treatment Tamiflu (oseltamivir phosphate) in the US for use in infants as young as two weeks with symptoms no longer than two days to help lessen the duration and severity of acute, uncomplicated forms of the virus.